Rita Leporati

The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)—Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab

Francesca Ligorio, Giovanni Fucà, Emma Zattarin et al. · Cancers · 2021 · 107 citations · Full text

Medicine, Immunology, Oncology +17

Recent advances and future strategies in first-line treatment of ES-SCLC

Igor Gómez‐Randulfe, Rita Leporati, B. K. Gupta et al. · European Journal of Cancer · 2024 · 29 citations · Full text

Medicine, Oncology, Chemotherapy +1

Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors

Emma Zattarin, Daniele Presti, Luigi Mariani et al. · npj Breast Cancer · 2023 · 25 citations · Full text

Medicine, Cancer Biology, Oncology +17

COVID-19 risk for patients undergoing anticancer treatment at the outpatient clinic of the National Cancer Institute of Milan: the COVINT study

Federico Nichetti, Marta Bini, Margherita Ambrosini et al. · ESMO Open · 2020 · 18 citations · Full text

Medicine, Clinical Sciences, Oncology +14

PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis

Giuseppe Lo Russo, Arsela Prelaj, James M. Dolezal et al. · Journal for ImmunoTherapy of Cancer · 2023 · 18 citations · Full text

Medicine, Immunology, Oncology +17